# Vanderbilt-Ingram Cancer Center: Phase 1 study started recruiting, 12 planned (Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma)

**Score:** 35/100

| Field | Value |
|---|---|
| Sponsor | Vanderbilt-Ingram Cancer Center |
| Sponsor type | Academic and hospital |
| Study | Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma |
| NCT ID | NCT07748988 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Refractory Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma |
| Intervention types | drug |
| Target enrollment | 12 |
| Site countries | United States |
| Posted | 2026-08-06 |
| Planned start | 2026-09-21 |
| Event | Started recruiting |
| Event date | 2026-09-21 |
| Last update posted | 2026-09-25 |

## Why this score
- Just started recruiting: sites, recruitment and supply are active.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07748988). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.